In NHE1 knockout murine glioma model, it was observed that the number of Treg was reduced, the PD-1 expression of T cells was increased, the sensitivity to temozolomide combined with anti-PD-1 therapy was markedly increased, and the median survival time was prolonged, further demonstrating that NHE1 could be an effective therapeutic target for glioma (Fig. 5c). Here, SLC9A1 is linked to central nervous system cancer.